Stripe, Anthropic and OpenAI Fund a Push Against Respiratory Infections

Stripe, together with the AI labs Anthropic and OpenAI, has backed a new initiative to prevent respiratory infections, an area where humanity still has no reliable weapon.

The problem everyone ignores

The common cold is the most widespread infection on the planet. The average adult catches it two to four times a year, and a child up to eight times. Despite decades of research, there is no vaccine or reliable preventive treatment. The most you can do right now is take vitamin C and keep away from sneezing colleagues. Rhinoviruses, adenoviruses and coronaviruses mutate constantly, which makes a universal defense extremely hard to develop.

The economic damage from colds in the US is estimated at tens of billions of dollars a year: missed work, lost productivity, doctor visits. The problem was long considered "too small" for serious investment, and that created a vacuum that private capital is now entering.

Who is putting up the money, and why

Stripe, the payments company of brothers Patrick and John Collison, has announced funding for a new research project in this field. Anthropic and OpenAI, the two leading players in AI, which in recent years have moved ever further beyond software, have joined the initiative.

Stripe already has experience funding science in unconventional ways. Through its Stripe Climate program, the company put money into CO₂ capture technologies when that market was in its infancy. The same logic applies to biomedical research: find an unsolved, underfunded problem and back it before it goes mainstream.

For Anthropic and OpenAI, taking part in medical projects is part of a strategy to demonstrate the practical value of AI. Both companies regularly point to the potential of their models in healthcare, and backing a specific research effort is a way to move from declarations to action.

How AI is changing medical research

AI models have already proved their worth in medicine: AlphaFold predicted the structures of almost all known proteins, and new models are speeding up the search for antiviral candidates. For respiratory infections, AI's capabilities include:

• Predicting viral mutations and assessing the risk of immune escape
• Analyzing millions of molecular candidates in days instead of years of laboratory trial and error
• Personalized forecasts of who is at risk of severe illness
• Speeding up clinical trials with synthetic data
• Identifying new drug targets that traditional methods missed

If even some of these capabilities deliver results against rhinoviruses, it will change the very logic of antiviral drug development.

What this means

The arrival of a Stripe, Anthropic and OpenAI alliance in medical research is another sign that the line between the tech and biomedical sectors is blurring. For decades the common cold remained an annoying trifle that nobody hurried to tackle seriously. Now resources and tools that researchers simply did not have before are being pointed at the problem.